|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
KAI Pharmaceuticals (2012)
Onyx Pharmaceuticals (2013)
Teneobio (2021)
|
|
gptkbp:ceo
|
gptkb:Robert_A._Bradway
|
|
gptkbp:clinical_trial
|
Phase 3 trials for various drugs
|
|
gptkbp:community_involvement
|
gptkb:Amgen_Foundation
Health and wellness programs
STEM education initiatives
Environmental sustainability efforts
Volunteerism programs
|
|
gptkbp:employees
|
~24,000
|
|
gptkbp:founded
|
gptkb:1980
|
|
gptkbp:founder
|
gptkb:George_B._Rathmann
|
|
gptkbp:headquarters
|
gptkb:Thousand_Oaks,_California
|
|
gptkbp:healthcare
|
gptkb:Biosimilars
Biologics
Therapeutic monoclonal antibodies
Small molecule drugs
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
AMGN
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:location
|
gptkb:United_States
|
|
gptkbp:market_cap
|
$134.5 billion (2023)
|
|
gptkbp:notable_person
|
gptkb:George_B._Rathmann
gptkb:David_W._Mott
gptkb:Robert_A._Bradway
gptkb:Kevin_Sharer
gptkb:Daniel_O'_Day
|
|
gptkbp:partnership
|
gptkb:Astra_Zeneca
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Novartis
|
|
gptkbp:products
|
gptkb:Enbrel
gptkb:Repatha
gptkb:Prolia
gptkb:Neulasta
|
|
gptkbp:research_focus
|
gptkb:Oncology
Inflammation
Nephrology
Neuroscience
Cardiovascular disease
Bone health
Metabolic disorders
Rare diseases
|
|
gptkbp:revenue
|
$25.42 billion (2022)
|
|
gptkbp:stock_symbol
|
gptkb:AMGN
|
|
gptkbp:subsidiary
|
gptkb:Onyx_Pharmaceuticals
Amgen Technology
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
www.amgen.com
|
|
gptkbp:bfsParent
|
gptkb:Amgen
|
|
gptkbp:bfsLayer
|
4
|